A. Taksin

发表

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity

J. Georges, B. Livarek, N. Baron, 2017, European heart journal cardiovascular Imaging.

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

R. Bouabdallah, H. Dombret, S. Chevret, 2007, Leukemia.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2011, Blood.

Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L

W. Vainchenker, N. Debili, F. Wendling, 1999 .

Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.

W. Vainchenker, N. Debili, F. Wendling, 1999, Blood.

Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.

A. Vekhoff, X. Thomas, E. Archimbaud, 2000, Leukemia research.

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

J. Georges, B. Livarek, N. Baron, 2016, Annales de cardiologie et d'angeiologie.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

A. Stamatoullas, P. Fenaux, L. Adès, 2011, Leukemia research.

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

A. Stamatoullas, B. Quesnel, P. Fenaux, 2010, Haematologica.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

H. Dombret, A. Stamatoullas, P. Fenaux, 2015, Leukemia research.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

P. Fenaux, S. Thépot, L. Adès, 2012, Leukemia research.

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

H. Dombret, S. Chevret, P. Fenaux, 2009 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

P033 Isolated del 20q defines a subgroup of MDS patients with lower blast counts and more frequent thrombocytopenia

S. Chevret, P. Fenaux, L. Adès, 2009 .

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

A. Stamatoullas, B. Quesnel, P. Fenaux, 2008 .

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.

W. Vainchenker, N. Debili, S. Barnache, 2002, Blood.

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

B. Quesnel, E. Wattel, P. Fenaux, 2009 .

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

P. Cony-Makhoul, S. de Botton, P. Rousselot, 2018, Leukemia & lymphoma.

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

K. Hoang-Xuan, M. Sanson, O. Casasnovas, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and prognostic significance of survivin in de novo acute myeloid leukaemia

F. Sigaux, H. Dombret, D. Altieri, 2000, British journal of haematology.

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

J. Larghero, P. Berthaud, P. Rousselot, 2003, Biochemical pharmacology.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

J. Tamburini, P. Morel, V. Leblond, 2007 .

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

I. Yakoub-Agha, X. Mariette, P. Morel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse

C. Preudhomme, P. Rousselot, Aline Renneville, 2014, American journal of hematology.

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

H. Dombret, P. Rousselot, H. de Thé, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined T reatment W ith A rsenic T rioxide a nd A ll-Trans- Retinoic A cid i n P atients W ith R elapsed A cute Promyelocytic L eukemia

P. Rousselot, O. Hermine, C. Chomienne, 2003 .

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy , for the prediction of subsequent cardiotoxicity

J. Georges, B. Livarek, N. Baron, 2017 .